METAVIA INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
METAVIA INC. (MTVA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.54% for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2024-08-14
- METAVIA INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.54%, a 105.81% increase year-over-year.
- METAVIA INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.72%.
- METAVIA INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-09-30 was 0.90%, a 125.00% increase year-over-year.
- METAVIA INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-09-30 was 0.40%.
- METAVIA INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 1.51%, a 45.09% decline from fiscal 2019.
- METAVIA INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 2.75%, a 1.85% increase from fiscal 2018.
- METAVIA INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2018 was 2.70%, a 35.00% increase from fiscal 2017.
- METAVIA INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2017 was 2.00%, a 66.67% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|---|
| 2024-06-30 | 3.54% 10-Q · filed 2024-08-14 | |||||
| 2023-06-30 | 3.54% 10-Q · filed 2023-08-09 | |||||
| 2023-03-31 | 3.54% 10-Q · filed 2023-05-12 | |||||
| 2022-03-31 | 1.72% 10-Q · filed 2023-05-12 | |||||
| 2021-09-30 | 0.90% 10-Q · filed 2021-11-15 | 0.90% 10-Q · filed 2022-11-14 | ||||
| 2020-12-31 | 1.51% 10-K · filed 2022-03-31 | |||||
| 2020-09-30 | 0.40% 10-Q · filed 2021-11-15 | 0.36% 10-Q · filed 2020-11-13 | 1.50% 10-Q · filed 2021-11-15 | 1.51% 10-Q · filed 2020-11-13 | ||
| 2020-06-30 | 1.71% 10-Q · filed 2021-08-16 | |||||
| 2020-03-31 | 1.71% 10-Q · filed 2021-05-17 | |||||
| 2019-12-31 | 2.75% 10-K · filed 2021-04-15 | |||||
| 2019-09-30 | 2.75% 10-Q · filed 2020-11-13 | |||||
| 2019-06-30 | 2.75% 10-Q · filed 2020-08-11 | |||||
| 2019-03-31 | 2.75% 10-Q · filed 2020-05-20 | |||||
| 2018-12-31 | 2.70% 10-K · filed 2019-03-18 | |||||
| 2018-09-30 | 2.70% 10-Q · filed 2019-11-08 | |||||
| 2018-06-30 | 2.90% 10-Q · filed 2019-08-09 | 2.70% 10-Q · filed 2019-08-09 | ||||
| 2018-03-31 | 2.50% 10-Q · filed 2019-05-09 | |||||
| 2017-12-31 | 2.00% 10-K · filed 2019-03-18 | |||||
| 2017-09-30 | 2.00% 10-Q · filed 2018-11-08 | 2.00% 10-Q · filed 2018-11-08 | ||||
| 2017-06-30 | 1.80% 10-Q · filed 2018-08-14 | 2.00% 10-Q · filed 2018-08-14 | ||||
| 2017-03-31 | 2.10% 10-Q · filed 2018-05-08 | |||||
| 2016-12-31 | 1.20% 10-K · filed 2019-03-18 | |||||
| 2016-09-30 | 1.20% 10-Q · filed 2017-11-13 | 1.20% 10-Q · filed 2017-11-13 | ||||
| 2015-12-31 | 1.70% 10-K · filed 2018-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |